Ligand News and Research

RSS

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

30 Sep 2014

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Ramucirumab effective second-line option for NSCLC

The monoclonal antibody ramucirumab, when added to second-line docetaxel, significantly improves the overall survival of patients with stage IV non-small-cell lung cancer, show the findings of the REVEL trial.

17 Sep 2014

Growth factors present in human breast milk may protect against intestinal damage

Studies Suggest that ErbB4 Receptor Activation May Be a Novel Therapeutic Avenue for Intestinal Diseases Involving Epithelial Cell Death, According to Research Published in The American Journal of Pathology

10 Sep 2014

Internal water channels can pave way for novel approaches in drug development

G protein-coupled receptors are the largest class of cell surface receptors in our cells, involved in signal transmission across the cell membrane.

9 Sep 2014

Cholera against cholera: an interview with Dr Bruce Turnbull, University of Leeds

Cholera bacteria, and other types of bacteria that cause diarrheal diseases, infect your intestines where they release AB5 protein toxins – that is they have a single toxic A-subunit that is linked to a pentamer of B-subunits that act as the delivery vehicle to transport the A-subunit into the cells.

8 Sep 2014

Scientists identify how immune cells use two critical receptors to clear dead cells from the body

In most of the tissues of the body, specialized immune cells are entrusted with the task of engulfing the billions of dead cells that are generated every day.

8 Sep 2014

Study compares FK506 and rapamycin for Schwann cell migration, peripheral nerve regeneration

FK506 possesses a well-studied neuroregenerative effect, stimulating neurite extension in the presence of nerve growth factor in vitro, and enhancing nerve regeneration following nerve crush injury and isografting.

30 Aug 2014

High PD-L1 expression linked to reduced survival in NSCLC

Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report.

28 Aug 2014

In vivo dopaminergic imaging strongly correlates with brain pathology

Striatal dopamine transporter binding, assessed using single-photon emission computed tomography, is strongly correlated with substantia nigra cell counts assessed at postmortem, say the authors of a study.

11 Aug 2014

Altering the circadian rhythm: an interview with Dr. Doug Kojetin, The Scripps Research Institute

The circadian rhythm is affected by many different stimuli—such as sleep and light, which are the most broadly appreciated ways—but also eating— all of which can modulate, or change, important processes in our bodies such as temperature, production of hormones or other signalling small molecules, cellular regeneration, and others.

6 Aug 2014

Researchers uncover 3D structure of neuroreceptor

Neurons are the cells of our brain, spinal cord, and overall nervous system. They form complex networks to communicate with each other through electrical signals that are carried by chemicals.

4 Aug 2014

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1).

29 Jul 2014

Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

There is considerable crosstalk between the CXCR4–CXCL12–CXCR7 axis and the mammalian target of rapamycin pathway in human renal cell carcinoma, and targeting the axis may overcome drug resistance to mTOR inhibitors, researchers suggest.

22 Jul 2014

New molecular analysis tool to detect targets for immunotherapy in early-stage breast cancers

Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers.

21 Jul 2014

Inflammatory shift in long-standing bipolar disorder

Patients with chronic bipolar disorder, but not those with schizophrenia, have a shift towards an M1 rather than an M2 macrophage response, research suggests.

15 Jul 2014

New potential avenues to predict and prevent ovarian cancer metastasis

Circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and metastasize to other organs, scientists at The University of Texas MD Anderson Cancer Center report in Cancer Cell.

15 Jul 2014

Eye exam for beta-amyloid correlates with levels in brain, detects people with Alzheimer's

A decreased ability to identify odors might indicate the development of cognitive impairment and Alzheimer's disease, while examinations of the eye could indicate the build-up of beta-amyloid, a protein associated with Alzheimer's, in the brain, according to the results of four research trials reported today at the Alzheimer's Association International Conference- 2014 (AAIC- 2014) in Copenhagen.

14 Jul 2014

Scientists discover new role for pair of compounds which alter circadian rhythm

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have discovered a surprising new role for a pair of compounds—which have the potential to alter circadian rhythm, the complex physiological process that responds to a 24-hour cycle of light and dark and is present in most living things.

8 Jul 2014

Scientists discover new compounds that could alter circadian rhythm